ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably [Seeking Alpha]
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: Seeking Alpha
The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point. Additionally, PROK targets the late-stage diabetic CKD demographic, which seems to be an overlooked demographic niche that Rilparencel could help. In my view, PROK's Rilparencel warrants a bullish outlook on the stock. Their financials also support their Q2 2027 topline results. So, it's still worth the risk. warat42/iStock via Getty Images ProKidney Corp. ( PROK ) is technically a kidney disease cell-therapy company. They develop their leading drug candidate called Rilparencel. This asset is an autologous kidney cell therapy for chronic kidney disease (CKD) related to type 2 diabetes (T2D). The drug is This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the c
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ProKidney to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright [Yahoo! Finance]Yahoo! Finance
- ProKidney (NASDAQ:PROK) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- ProKidney (NASDAQ:PROK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
PROK
Earnings
- 11/10/25 - In-Line
PROK
Sec Filings
- 2/2/26 - Form 8-K
- 1/12/26 - Form 8-K
- 11/19/25 - Form EFFECT
- PROK's page on the SEC website